Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921591 | 0.82 | CCR5 (0.32) | — | |
| SCHEMBL15758321 | 0.80 | SLC6A1 (0.35) | PNMTSLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL8795601 | 0.73 | — | — | |
| SCHEMBL3575976 | 0.73 | KDM1A (0.35) | PNMT | |
| SCHEMBL28392434 | 0.73 | MEN1 (0.33) | — | |
| SCHEMBL30889537 | 0.72 | SLC6A1 (0.30) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL30889509 | 0.72 | SLC6A1 (0.30) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL30089047 | 0.70 | KDM1A (0.44) | — | |
| SCHEMBL27209614 | 0.70 | KDM1A (0.44) | — | |
| SCHEMBL9323765 | 0.68 | GSR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149678-A1 | Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto | ORONSKY BRYAN T (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149678-A1 | Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto | NPM1, MCL1, BCL9 | PNMT 301/4885SLC6A1 1931/4885GABRA5 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.